Literature DB >> 12509594

Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit.

Michael D Mallory1, David K Shay, Joanne Garrett, W Clayton Bordley.   

Abstract

OBJECTIVE: High incidence, rising admission rates, and relatively ineffective therapies make the management of bronchiolitis controversial. Since 1980, the rate of hospitalization for children with bronchiolitis has increased by nearly 250%, whereas mortality rates for the disease have remained constant. It has been speculated that the increasing use of pulse oximetry has lowered the threshold for admission and may have contributed to the rise in bronchiolitis-related admissions. The objective of this study was to describe pediatric emergency medicine physicians' management preferences regarding infants with moderately severe bronchiolitis and to assess the influence of specific differences in oxygen saturation as measured by pulse oximetry (SpO2) and respiratory rate (RR) on the decision to admit.
METHODS: Physicians who are members of the American Academy of Pediatrics Section of Emergency Medicine and living in the United States were randomized into 4 groups and mailed a survey that contained 1 of 4 vignettes. Vignettes were identical except for given SpO2 values (94% or 92%) and RR (50/min or 65/min). Subjects were asked to answer questions regarding laboratory tests, treatment options, and the decision to admit for the patient in their vignette.
RESULTS: We received completed surveys from 519 (64%) of the 812 physicians contacted. Most respondents recommended use of bronchodilators (96%), nasal suction (82%), and supplemental oxygen (57%). Few respondents recommended decongestants (9%), steroids (8%), or antibiotics (2%). When asked to rank therapies, respondents gave nasal suction 182 number 1 votes; bronchodilators received 164. The decision to admit varied with SpO2 and RR. Forty-three percent of respondents who received a vignette featuring SpO2 of 94% and a RR of 50/min recommended admission for the infant in their vignette. Fifty-eight percent recommended admission when the vignette SpO2 was 94% and RR was 65/min (chi2 = 5.021). Respondents who received a vignette with SpO2 of 92% were nearly twice as likely to recommend admission: 83% recommended admission when vignette RR was 50/min, and 85% recommended admission when vignette RR was 65/min (chi2 = 0.126).
CONCLUSIONS: When treating infants with moderately severe bronchiolitis, pediatricians who work in emergency departments frequently use bronchodilators and nasal suction, 2 practices for which supporting data are either conflicting (bronchodilators) or nonexistent (nasal suction). In addition, their decisions to admit differ markedly on the basis of only a 2% difference in SpO2. It is possible that increased reliance on pulse oximetry has contributed to the increase in bronchiolitis hospitalization rates seen during the past 2 decades.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12509594     DOI: 10.1542/peds.111.1.e45

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  36 in total

1.  Has the hospital become the place not to be for infants with bronchiolitis?

Authors:  Kris De Boeck
Journal:  Eur J Pediatr       Date:  2012-10-09       Impact factor: 3.183

2.  Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians.

Authors:  Alexandra E Shields; David Blumenthal; Kevin B Weiss; Catherine B Comstock; Douglas Currivan; Caryn Lerman
Journal:  J Gen Intern Med       Date:  2005-02       Impact factor: 5.128

Review 3.  Cardiorespiratory and Pulse Oximetry Monitoring in Hospitalized Children: A Delphi Process.

Authors:  Amanda C Schondelmeyer; Maya L Dewan; Patrick W Brady; Kristen M Timmons; Rhonda Cable; Maria T Britto; Christopher P Bonafide
Journal:  Pediatrics       Date:  2020-07-17       Impact factor: 7.124

4.  Validation of a scale to assess the severity of bronchiolitis in a population of hospitalized infants.

Authors:  Diana M Duarte-Dorado; Danitza S Madero-Orostegui; Carlos E Rodriguez-Martinez; Gustavo Nino
Journal:  J Asthma       Date:  2013-09-19       Impact factor: 2.515

5.  Prospective multicenter study of bronchiolitis: predictors of an unscheduled visit after discharge from the emergency department.

Authors:  Agatha Norwood; Jonathan M Mansbach; Sunday Clark; Muhammad Waseem; Carlos A Camargo
Journal:  Acad Emerg Med       Date:  2010-04       Impact factor: 3.451

6.  Impact of home oxygen therapy on hospital stay for infants with acute bronchiolitis.

Authors:  Marie Gauthier; Melanie Vincent; Sylvain Morneau; Isabelle Chevalier
Journal:  Eur J Pediatr       Date:  2012-09-27       Impact factor: 3.183

7.  Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan.

Authors:  Kecia N Carroll; Tebeb Gebretsadik; Marie R Griffin; Pingsheng Wu; William D Dupont; Edward F Mitchel; Rachel Enriquez; Tina V Hartert
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

8.  Apnea in children hospitalized with bronchiolitis.

Authors:  Alan R Schroeder; Jonathan M Mansbach; Michelle Stevenson; Charles G Macias; Erin Stucky Fisher; Besh Barcega; Ashley F Sullivan; Janice A Espinola; Pedro A Piedra; Carlos A Camargo
Journal:  Pediatrics       Date:  2013-10-07       Impact factor: 7.124

Review 9.  Glucocorticoids for acute viral bronchiolitis in infants and young children.

Authors:  Ricardo M Fernandes; Liza M Bialy; Ben Vandermeer; Lisa Tjosvold; Amy C Plint; Hema Patel; David W Johnson; Terry P Klassen; Lisa Hartling
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

10.  Prospective multicenter study of children with bronchiolitis requiring mechanical ventilation.

Authors:  Jonathan M Mansbach; Pedro A Piedra; Michelle D Stevenson; Ashley F Sullivan; Tate F Forgey; Sunday Clark; Janice A Espinola; Carlos A Camargo
Journal:  Pediatrics       Date:  2012-08-06       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.